| Companies |
 |
|
2011 MAIN/Stage Presenting Companies
ABT Molecular Imaging, Inc.
A medical imaging company developing and manufacturing the "Dose on Demand" Biomarker Generator for simple and convenient unit dose production of positron emission tomography (PET) biomarkers and radioisotopes.
Altor BioScience Corporation
A biopharmaceutical company utilizing its soluble T-cell antigen receptor (STAR™), Tissue Factor antagonist, and IL-15 scaffold technologies for the discovery, development, and commercialization of immunotherapeutics for the treatment of cancer, viral infections, inflammatory disorders, and autoimmune diseases.
CivaTech Oncology, Inc.
A medical device company developing and marketing low-dose-rate (LDR) radioactive polymer-based devices to provide optimized therapy for breast, lung, and prostate cancers.
Elenza, Inc.
A medical device company developing an electro-active "AutoFocal" Intraocular Lens designed to automatically adjust focusing power electronically, in milliseconds, to maintain constant in-focus vision giving patients a complete visual range, providing effective near, intermediate, and distance vision.
Envoy Therapeutics, Inc.
A biopharmaceutical company utilizing its bacTRAP® technology to identify proteins in vivo that are produced by specific cells in the brain without requiring the isolation of those cells, and developing molecules that selectively act on the target proteins to treat neurological and psychiatric diseases.
Liquidia Technologies
A nanomedicine company utilizing its PRINT® particle engineering platform to design and develop specialized particles of controlled size, shape, and chemistry for the tailored delivery of biological and small molecule therapeutics.
Metabolon, Inc.
A diagnostic products and services company utilizing its biochemical profiling platform to provide a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease.
Viamet Pharmaceuticals, Inc.
A biotechnology company utilizing its proprietary metal-binding approach, Metallophile® Technology, to discover and develop therapeutically improved analogues of known metalloenzyme inhibitors for treatments in the fields of inflammation, infectious disease, and oncology.
2011 EARLY/Stage Presenting Companies
ActivBiotics Pharma
A pharmaceutical company developing anti-infectives for chronic and infectious disease markets with its lead compound, Rifalazil (RLZ), in Phase II clinical development for chlamydia.
Arbovax, Inc.
A biotechnology company utilizing its vaccine development technology, which renders insect-borne viruses incapable of replicating in mammalian cells, to develop vaccines against insect-borne diseases.
Claro Scientific, LLC
A diagnostic systems company developing portable, low-cost hardware and software systems that rapidly provide comprehensive sample information without reagents for medical diagnostics, biomanufacturing, biodefense, and environmental monitoring.
Clinical Sensors, Inc.
A diagnostic systems company utilizing its sensor membrane technology to develop facile, accurate diagnostic tests and point-of-care devices, including a nitric oxide sensor for early detection of sepsis and treatment monitoring.
GLG Pharma, LLC
A biotechnology company developing STAT3 inhibitors and corresponding diagnostics for the treatment of cancer.
G-Zero Therapeutics
A biotechnology company developing small molecule-based therapeutics to prevent bone marrow suppression caused by radiation therapy or chemotherapy.
iTi Health
A biotechnology company utilizing its platform technology, PHAGEMARK, to identify and develop biomarkers and binding peptides for targeted therapeutics and diagnostic imaging tools, such as plectin 1 (a pancreatic cancer biomarker) and a plectin-targeted imaging agent.
KOR Therapies, LLC
A biopharmaceutical company developing small molecule inhibitors targeted to a family of novel ion channels to prevent and treat arrhythmia and heart failure.
Lumena Pharmaceuticals
A pharmaceutical company developing treatments for metabolic diseases, such as obesity and type 2 diabetes, through non-systemically absorbed compounds targeted to the lumen of the gut.
Madeira Therapeutics, LLC
A drug development company focused on reformulating adult drugs for better dosage control in children, including drugs for early heart disease and acute chronic pain management.
NellOne Therapeutics, Inc.
A biotechnology company developing NELL1 protein therapeutics for regenerating heart muscle after myocardial infarction and skeletal muscle for wound healing.
Pique Therapeutics
A biopharmaceutical company developing therapeutic vaccines for the treatment of cancer, including PT 107 in Phase II clinical development for the treatment of non-small cell lung cancer.
Smart Perfusion, LLC
A medical device company developing VasoWave™ systems for characterizing, conditioning, restoring, and preserving organs outside the body before transplantation.
SphingoGene, Inc.
A biotechnology company developing small molecule therapeutics that modify ceramide metabolism to overcome resistance to chemo and radiation therapy and promote apoptosis in cancer cells.
Vitasol, Inc.
A biotechnology company developing RESUSCINEX™, an injectable resuscitation fluid that restores a hemorrhagic patients' critical body fluid levels more efficiently with fewer side effects.
2011 BIO/Plan Competition Semi-Finalists
Composite Hydrogel as Healing Aid for Non-Union Bone Injuries
Category: Medical Device
Affiliation: University of Virginia
Principals: Joshua R. Bush
Compounds Targeting the CRLF2 Receptor in Leukemia
Category: Pharma/Biotech
Affiliation: University of Florida
Principals: William Slayton, David Ostrov, Emil Popp
DiagNano
Category: Diagnostic
Affiliation: Emory University
Principals: Shuming Nie, Brad Kairdolf
Infusensor
Category: Medical Device/Diagnostic
Affiliation: University of Tennessee Health Science Center
Principals: Edward Chaum
Microneedle for Ocular Delivery
Category: Medical Device
Affiliation: Emory University/Georgia Institute of Technology
Principals: Henry Edelhauser, Mark Prausnitz
Viamune, Inc. (MUC1 Tripartite Vaccine)
Category: Pharma/Biotech
Affiliation: University of Georgia
Principals: Alex Harvey
Removal of Blood Phosphates in Hemodialysis Patients
Category: Medical Device
Affiliation: UNC at Chapel Hill, NC State University
Principals: Melanie Joy, Marian McCord
Silica-Based Nanoparticles as Therapeutics for Osteoporosis
Category: Pharma/Biotech
Affiliation: Emory University
Principals: M. Neale Weitzmann, Jim Sikorski
Suction Enteroscope
Category: Medical Device
Affiliation: Private/University of Florida
Principals: Stephen Kennedy, Mihir Wagh
Transcatheter Valve Technology
Category: Medical Device
Affiliation: Emory University
Principals: Muralidhar Padala, Vinod Thourani
| 
